(Q37716669)

22 August 2017

1 reference

title

What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? (English)

1 reference

22 August 2017

0 references

P D Miller

1

1 reference

22 August 2017

R J Derman

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

23 March 2010

1 reference

Osteoporosis International

22 August 2017

published in

1 reference

22 August 2017

volume

21

1 reference

22 August 2017

issue

11

1 reference

22 August 2017

page(s)

1793-1802

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-010-1208-3

22 August 2017

exact match

0 references

cites work

Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1208-3

Redefining osteoporosis treatment: Who to treat and how long to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1208-3

Calcium intake and disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1208-3

Optimal Thresholds, Linear or Nonlinear Relationships of Fracture Risk Reduction With Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1208-3

A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study

21 January 2018

1 reference

12 December 2020

Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study

1 reference

12 December 2020

Denosumab: anti-RANKL antibody

1 reference

12 December 2020

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

12 December 2020

Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis

1 reference

12 December 2020

Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial

1 reference

12 December 2020

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

1 reference

12 December 2020

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Strategies for the prevention and treatment of osteoporosis during early postmenopause

1 reference

12 December 2020

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

12 December 2020

Osteoporosis. Part III--Not just for bone loss: potential benefits of calcium and vitamin D for overall general health

1 reference

12 December 2020

Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

FRAX and the assessment of fracture probability in men and women from the UK

1 reference

12 December 2020

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

1 reference

12 December 2020

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

1 reference

12 December 2020

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

1 reference

12 December 2020

Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.

1 reference

12 December 2020

FRAX and its applications to clinical practice

1 reference

12 December 2020

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

1 reference

12 December 2020

Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women

1 reference

12 December 2020

Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society

1 reference

12 December 2020

Hip fracture in women without osteoporosis

1 reference

12 December 2020

Update on the use of bisphosphonates in the management of postmenopausal osteoporosis by obstetricians-gynecologists

1 reference

12 December 2020

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

12 December 2020

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update

1 reference

12 December 2020

Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials

1 reference

12 December 2020

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

1 reference

12 December 2020

Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance

1 reference

12 December 2020

A new approach to menopausal therapy: the tissue selective estrogen complex

1 reference

12 December 2020

Analgesic efficacy of calcitonin for vertebral fracture pain

1 reference

12 December 2020

Should symptomatic menopausal women be offered hormone therapy?

1 reference

12 December 2020

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

12 December 2020

Underutilization of antiosteoporotic drugs by orthopedic surgeons for prevention of a secondary osteoporotic fracture

1 reference

12 December 2020

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

1 reference

12 December 2020

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

A revised clinician's guide to the prevention and treatment of osteoporosis.

1 reference

12 December 2020

Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.

1 reference

12 December 2020

Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women

1 reference

12 December 2020

Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women

1 reference

12 December 2020

Low-energy femoral shaft fractures associated with alendronate use.

1 reference

12 December 2020

Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women

1 reference

12 December 2020

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

1 reference

12 December 2020

Secondary prevention of hip fractures among the hospitalized elderly: are we doing enough?

1 reference

12 December 2020

Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women

1 reference

12 December 2020

Epidemiology of osteoporosis

1 reference

12 December 2020

Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?

1 reference

12 December 2020

Effects of conjugated equine estrogen on stroke in the Women's Health Initiative

1 reference

12 December 2020

Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial

1 reference

12 December 2020

Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women.

1 reference

12 December 2020

Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial

1 reference

12 December 2020

Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study

1 reference

12 December 2020

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

1 reference

12 December 2020

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

12 December 2020

Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.

1 reference

12 December 2020

Anti-resorptives in the management of osteoporosis

1 reference

12 December 2020

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

1 reference

12 December 2020

Compliance and persistence with osteoporosis therapies

1 reference

12 December 2020

Calcium plus vitamin D supplementation and the risk of fractures

1 reference

12 December 2020

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Osteoporosis treatments and adverse events

1 reference

12 December 2020

Non-estrogen treatments for osteoporosis: an evidence-based review

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Calcitonins and osteoporosis

1 reference

12 December 2020

1 reference

12 December 2020

Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women

1 reference

12 December 2020

Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial

1 reference

12 December 2020

Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women

1 reference

12 December 2020

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

1 reference

12 December 2020

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies

1 reference

12 December 2020

Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens

1 reference

12 December 2020

Denosumab in postmenopausal women with low bone mineral density

1 reference

12 December 2020

Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw.

1 reference

12 December 2020

Salmon calcitonin: a review of current and future therapeutic indications

1 reference

12 December 2020

Bone markers--new aspects.

1 reference

12 December 2020

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

1 reference

12 December 2020

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

12 December 2020

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

1 reference

12 December 2020

The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone

1 reference

12 December 2020

A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women

1 reference

12 December 2020

1 reference

12 December 2020

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

1 reference

12 December 2020

Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction

1 reference

12 December 2020

Highlights from the latest WHI publications and the latest North American Menopause Society position statement on use of menopausal hormone therapy

1 reference

12 December 2020

Update on the treatment of post-menopausal osteoporosis

1 reference

12 December 2020

Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark

1 reference

12 December 2020

Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

1 reference

12 December 2020

Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study

1 reference

12 December 2020

Postmenopausal osteoporosis and hormone replacement therapy

1 reference

12 December 2020

Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation

1 reference

12 December 2020

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment

1 reference

12 December 2020

Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society

1 reference

12 December 2020

Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

1 reference

12 December 2020

Adverse events reported by postmenopausal women in controlled trials with raloxifene

1 reference

12 December 2020

Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation.

1 reference

12 December 2020

Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women

1 reference

12 December 2020

Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk

1 reference

12 December 2020

10.1007/S00198-010-1208-3

Identifiers

DOI

1 reference

22 August 2017

1 reference